Season 1 Episode 211
Most headlines make billion-dollar beauty acquisitions sound like the ultimate win, build fast, sell big, cash out. We see it differently. In this episode, we share why we turn down investor offers and why outside funding often marks the end of real innovation.
We break down what happens when profit-first investors take over: pressure to cut ingredient quality, cheapen packaging, and churn out unnecessary products. We explain why that goes against everything we build at Young Goose, science-backed, high-integrity formulas that put skin longevity first.
We talk about the kind of growth we do want, how we protect our creative freedom, and why staying independent keeps our research bold and our products uncompromised.
If you want to know what really happens behind the headlines, and why we believe mission matters more than the biggest buyout offer, this episode takes you inside our vision for the future.
What's Discussed:
(00:08) Why We Refuse Investor Money (Even When It’s Millions)
(15:53) The Growth Path That Keeps Our Innovation Alive
(20:40) How Our Ingredients Influence the Entire Skincare Industry
(22:31) Why We Compare Ourselves to Aesop — Not Rhodes or Rare
(24:17) The Real Reason We’re in Skincare (It’s Not the Buyout)
Find More from Young Goose
Published on 5 days, 13 hours ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate